Property | Value |
?:abstract
|
-
The sudden worldwide outbreak of Coronavirus Disease 2019 (COVID-19) has certainly provided new challenges in the management of acute ischaemic stroke, and the risk-benefit ratio of intravenous thrombolysis in COVID-19 positive patients is not well known. We describe four COVID-19 patients treated with intravenous thrombolysis for acute ischaemic stroke. Although rt-PA administration is the main therapeutic strategy, our patients experienced unpredictable complications and showed atypical features: the overall mortality was very high. In conclusion, in this article, we provide information about these cases and discuss the possible explanation behind this trend.
|
?:creator
|
|
?:doi
|
-
10.1007/s10072-020-04591-3
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/44e9687ba033dc0505d32b11d75bbfc9b17dd709.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7354364.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients
|
?:type
|
|
?:year
|
|